Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00936741 · OUTCOME

Number of Participants With Adverse Events

An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome · Source last updated 2014-04-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
Up to three years.

What was measured

Subjects who received at least one dose of mifepristone were included in the safety analysis.

Analysis population: Subjects who received one dose of study drug were included in the safety and ITT analyses.

Groups in this outcome

Open-label

mifepristone at doses from 300 mg/day up to 1200 mg/day daily

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Open-label30

Reported measurements

Source class 1
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Open-label30Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        30
denoms
  1. counts
    1. group Id
      OG000
      value
      30
    units
    Participants
description
Subjects who received at least one dose of mifepristone were included in the safety analysis.
groups
  1. description
    mifepristone at doses from 300 mg/day up to 1200 mg/day daily
    id
    OG000
    title
    Open-label
param Type
NUMBER
population Description
Subjects who received one dose of study drug were included in the safety and ITT analyses.
reporting Status
POSTED
time Frame
Up to three years.
title
Number of Participants With Adverse Events
type
PRIMARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice